

# Research Grade Etokimab

## Summary

---

<b>Catalog No.</b>	DHB74001
<b>Alternative Names</b>	ANB020, CAS: 2022981-44-6,IL33
<b>Clone ID</b>	Etokimab
<b>Host species</b>	Humanized
<b>Species reactivity</b>	Human
<b>Form</b>	Liquid
<b>Storage buffer</b>	0.01M PBS, pH 7.4.
<b>Concentration</b>	1 mg/ml
<b>Purity</b>	>95% as determined by SDS-PAGE.
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1-kappa
<b>Applications</b>	Research Grade Biosimilar
<b>Target</b>	NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11
<b>Purification</b>	Protein A/G purified from cell culture supernatant.
<b>Endotoxin level</b>	Please contact with the lab for this information.
<b>Expression system</b>	Mammalian Cells
<b>Accession</b>	O95760

**Stability and Storage**

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.


**Note**

For research use only. Not suitable for clinical or therapeutic use.

## Description

ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobulin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.

## Data Image



SDS PAGE for Etokimab